TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28520774

Group type: EXPERIMENTAL
Intervention: Outdoor mountain hiking
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Indoor treadmill walking
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sedentary control situation
Number of subjects: 42
Study: 26387707

Group type: EXPERIMENTAL
Intervention: Retention materials (annual newsletter)
Number of subjects: 41482

Group type: COMPARATOR
Intervention: Token gift or birthday card
Number of subjects: 41482

Group type: COMPARATOR
Intervention: Use of a secure website for study forms
Number of subjects: 41482
Study: 23468866

Group type: EXPERIMENTAL
Intervention: Prosigne®
Number of subjects: 57

Group type: COMPARATOR
Intervention: Botox®
Number of subjects: 57
Study: 21571703

Group type: EXPERIMENTAL
Intervention: Supervised high‐intensity progressive resistance exercise training (PRT) for 16 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 58
Study: 19292215

Group type: EXPERIMENTAL
Intervention: Screw fixation (2 x 6.5‐mm cancellous screws)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Screwless fixation
Number of subjects: 116
Study: 16997300

Group type: EXPERIMENTAL
Intervention: Endometriosis group (IVF-ET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tubal infertility group (IVF-ET)
Number of subjects: 60
Study: 12799786

Group type: EXPERIMENTAL
Intervention: Stent-protected angioplasty (SPAC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Endarterectomy (CEA)
Number of subjects: 350
Study: 11044229

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 35

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 35
Study: 11990135

Group type: COMPARATOR
Intervention: TE subjects (terminated early) at 18 degrees C
Number of subjects: 0

Group type: COMPARATOR
Intervention: TE subjects (terminated early) at 22 degrees C
Number of subjects: 0

Group type: COMPARATOR
Intervention: TE subjects (terminated early) at 26 degrees C
Number of subjects: 0

Group type: COMPARATOR
Intervention: TE subjects (terminated early)
Number of subjects: 0
Study: 8375835

Group type: EXPERIMENTAL
Intervention: Recent regular use criteria (any past period of daily or weekly use plus any use during the 30 days before hospitalization)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: DSM-III-R substance use diagnoses
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Recent regular use criteria
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Patients identified by both methods
Number of subjects: 474
Study: 3025388

Group type: EXPERIMENTAL
Intervention: Soy protein diets (25% replacement with soy flour, soy concentrate, or soy isolate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soy isolate as the main protein source
Number of subjects: 8

Group type: COMPARATOR
Intervention: Meat protein diet
Number of subjects: 8
Study: 28437283

Group type: EXPERIMENTAL
Intervention: Enhanced Educational Program (EEP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard Institutional Instruction
Number of subjects: 42
Study: 27609058

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy or uterine preservation procedure (Uterine Trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginal sacrospinous fixation or abdominal sacrocolpopexy (Vault Trial)
Number of subjects: 0
Study: 23919920

Group type: EXPERIMENTAL
Intervention: Synbiotic mixture (two Lactobacillus strains, one Bifidobacterium strain, one Propionibacterium strain and galacto‐oligosaccharides (32 g/l))
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 52
Study: 22353614

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/d)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/d)
Number of subjects: 46
Study: 20864072

Group type: EXPERIMENTAL
Intervention: Resistance exercise program with an elastic band (EG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group not submitted to the exercise program (CG)
Number of subjects: 64
Study: 18758308

Group type: EXPERIMENTAL
Intervention: Maintenance irinotecan therapy (100 mg/m IV on days 1, 8, and 15, every 4 weeks up to six cycles)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 120
Study: 15930237

Group type: EXPERIMENTAL
Intervention: Dietary intervention to lower saturated-fat and cholesterol intake
Number of subjects: 663

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 663
Study: 12822636

Group type: COMPARATOR
Intervention: Standard steel-tip end-hole cannula (7.3 mm)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Soft-Flow cannula (8.0 mm)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dispersion cannula (8.0 mm)
Number of subjects: 9
Study: 10803042

Group type: EXPERIMENTAL
Intervention: Calcium antagonists and angiotensin-converting-enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs (beta-blockers or diuretics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 8644803

Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with air
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with 5% perfluoropropane
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with 10% perfluoropropane
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with 16% perfluoropropane
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Recombinant TGF‐beta 2
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 1992963

Group type: COMPARATOR
Intervention: 14 mg/kg per day of oral cyclosporine for 4 weeks (Group 1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 6 mg/kg per day of oral cyclosporine for 1 to 3 months (Group 2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined data for both groups for the first 4 weeks of therapy
Number of subjects: 49
Study: 6336878

Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention (with reinfarction included)
Number of subjects: 733
Study: 31004837

Group type: EXPERIMENTAL
Intervention: ADHEAR
Number of subjects: 10

Group type: COMPARATOR
Intervention: BCDS
Number of subjects: 10
Study: 28414020

Group type: EXPERIMENTAL
Intervention: Complex community-based intervention to reduce alcohol consumption, including face-to-face sessions and text messages.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Active control in the form of a conventional alcohol brief intervention.
Number of subjects: 69
Study: 26868949

Group type: EXPERIMENTAL
Intervention: Behavioural intervention delivered by a practice nurse or healthcare assistant
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard care offered in General Practice
Number of subjects: 350
Study: 25096168

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel/carboplatin (PCw) - paclitaxel 90mg/m², cisplatin 70mg/m² or carboplatin AUC 4
Number of subjects: 267

Group type: COMPARATOR
Intervention: Three-weekly paclitaxel/carboplatin (PC3w) - paclitaxel 175mg/m², cisplatin 75mg/m² or carboplatin AUC 6
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 267
Study: 21696933

Group type: EXPERIMENTAL
Intervention: E0.25 (esmolol 0.25 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: E0.5 (esmolol 0.5 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: E1.0 (esmolol 1.0 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (E0 - no esmolol)
Number of subjects: 200
Study: 19563327

Group type: EXPERIMENTAL
Intervention: IMZ implant system (two-stage cylinder type)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Brånemark implant system (two-stage screw type)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ITI implant system (one-stage screw type)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study: 18154126

Group type: EXPERIMENTAL
Intervention: Local ultrasound hyperthermia (41-45 deg.C, TTD-36 Gy)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard radiotherapy (TTD-60-110 Gy)
Number of subjects: 174
Study: 15220228

Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthening (ATL) and total contact casting (TCC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Total contact casting (TCC)
Number of subjects: 28
Study: 11587240

Group type: EXPERIMENTAL
Intervention: Structured care outpatient treatment program
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Long duration of heart failure and low blood hemoglobin concentration
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low MMSE score
Number of subjects: 78
Study: 10446036

Group type: EXPERIMENTAL
Intervention: Brief intervention through community dental care including annual inquiries about smoking, showing photographs of harmful effects, self-examination with a mirror, and counseling based on smoking habits.
Number of subjects: 2586

Group type: COMPARATOR
Intervention: Usual care control group (no specific intervention details provided).
Number of subjects: 2586
Study: 7872284

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (1 g/day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 2143129

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion at 0.25 micrograms/min
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion at 2.0 micrograms/min
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of ANF concentrations between young and elderly subjects
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Correction of changes in systolic blood pressure and mean arterial pressure for higher ANF levels in elderly
Number of subjects: 17
Study: 332184

Group type: EXPERIMENTAL
Intervention: 4 gm aspirin daily for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31188696

Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice (TCJ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 29342509

Group type: EXPERIMENTAL
Intervention: Combination format (numbers + IA + BS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balance Scales (BS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numbers-only format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Icon Array (IA) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Icon Array (IA) with or without BS
Number of subjects: 0
Study: 26403252

Group type: EXPERIMENTAL
Intervention: Web-based resource providing personalized health history, late effects information, and resources via a password-protected Web portal
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard of care (physician counseling) only
Number of subjects: 52
Study: 24994869

Group type: EXPERIMENTAL
Intervention: Preservative-free eye drops (0.1% sodium hyaluronate and 0.1% fluorometholone for the first month; 0.1% sodium hyaluronate and 0.05% cyclosporine for the second and third months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Preserved eye drops
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preservative-free eye drops
Number of subjects: 100
Study: 22225814

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard-dose aciclovir (400 mg twice daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose aciclovir (800 mg three times daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard-dose valaciclovir (500 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose valaciclovir (1 g three times daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard-dose valaciclovir
Number of subjects: 90
Study: 20551816

Group type: EXPERIMENTAL
Intervention: Preoperative incentive spirometry (group PR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Postoperative incentive spirometry (group PO)
Number of subjects: 50
Study: 18492750

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) oral (os)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ergocalciferol (D2) oral (os)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) intramuscular (im)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ergocalciferol (D2) intramuscular (im)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 32
Study: 16171713

Group type: EXPERIMENTAL
Intervention: Flow-mediated vasodilation (FMD)
Number of subjects: 66
Study: 11578300

Group type: EXPERIMENTAL
Intervention: Standardized meal stimulation test (563 kcal)
Number of subjects: 50
Study: 9753533

Group type: EXPERIMENTAL
Intervention: Patient Competency Rating Scale (PCRS) administered to TBI patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patient Competency Rating Scale (PCRS) administered to controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Difference scores (PCRS-P minus PCRS-R)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation with Glasgow Coma Scale (GCS) scores and posttraumatic amnesia (PTA) estimates
Number of subjects: 30
Study: 8164820

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 1 mg/kg (young controls)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Invalid cue performance (AD patients)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Valid cue performance (all groups)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Invalid cue performance (all groups)
Number of subjects: 35
Study: 3047336

Group type: EXPERIMENTAL
Intervention: Androgen priming for three days before and on the day of chemotherapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Androgen priming
Number of subjects: 85
Study: 2043503

Group type: EXPERIMENTAL
Intervention: Summary letter sent to patients after consultations (Experimental group, N = 23)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (letter to GP only, N = 29)
Number of subjects: 52
Study: 794558

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (25-(OH)D3) 25 to 200 mug/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (25-(OH)D3) 25 to 50 mug/day with calcium supplementation (0.5 to 1.5 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Calcium supplementation alone (0.5 to 0.75 g/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (25-(OH)D3)
Number of subjects: 14
Study: 30031748

Group type: EXPERIMENTAL
Intervention: Targeted neuromuscular exercises for 12 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 75
Study: 27376544

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (260 mJ/4 Hz) re‐wetting with chlorhexidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (260 mJ/4 Hz) re‐wetting with deionized water
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional method re‐wetting with chlorhexidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional method re‐wetting with deionized water
Number of subjects: 20
Study: 24831043

Group type: EXPERIMENTAL
Intervention: 4-week video plus educational booklet intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 92
Study: 23561712

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21364527

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural group treatment (eight sessions)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waiting‐list control group
Number of subjects: 98
Study: 19630485

Group type: EXPERIMENTAL
Intervention: Single nephrostomy tube placement after multitract PCNL (Group A)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Multiple nephrostomy tubes (Group B)
Number of subjects: 192
Study: 17374657

Group type: EXPERIMENTAL
Intervention: High-fat meal (42 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat meal (1 g)
Number of subjects: 30
Study: 15325832

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 18325

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 18325

Group type: COMPARATOR
Intervention: ibuprofen 800 mg three times daily
Number of subjects: 18325
Study: 11251007

Group type: COMPARATOR
Intervention: Granisetron (10 microg/kg IV) + Dexamethasone (20 mg PO)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Granisetron (10 microg/kg IV) + MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: MK-869 (400 mg PO evening before and pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Number of subjects: 351
Study: 9891256

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention (8-week duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 8281644

Group type: EXPERIMENTAL
Intervention: Autonomic blockade using 0.04 mg/kg atropine and 0.2 mg/kg propranolol
Number of subjects: 8
Study: 2660561

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times a day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of sucralfate 1 g three times a day and 400 mg cimetidine at night
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sucralfate maintenance 2 g daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30408282

Group type: EXPERIMENTAL
Intervention: Individual stepped-care stress-management intervention (CBT techniques, completed within 26 weeks)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Step 2 intervention (additional 3-8 sessions for patients with significant stress)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (patients who did not report clinically significant stress levels participated in only one counseling session)
Number of subjects: 291
Study: 27568306

Group type: COMPARATOR
Intervention: Incisal anesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Block anesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mucosal anesthesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reference group
Number of subjects: 45
Study: 25873044

Group type: EXPERIMENTAL
Intervention: HBPTM plus individualized, culturally‐tailored, telephone‐based NCM
Number of subjects: 450

Group type: COMPARATOR
Intervention: HBPTM alone
Number of subjects: 450
Study: 23221809

Group type: EXPERIMENTAL
Intervention: Tailored cardiac rehabilitation program
Number of subjects: 236

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Both CR programs
Number of subjects: 236
Study: 21552054

Group type: EXPERIMENTAL
Intervention: Topical sucralfate (7% sucralfate ointment applied twice daily for 6 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (petroleum jelly ointment applied twice daily for 6 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical sucralfate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19803236

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with TDP irradiation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Herbal steaming and washing therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic treatment (Vitamin B1, Vitamin B12, compound Vitamin B, small splint for wrist protection)
Number of subjects: 60
Study: 16908790

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/d)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Progestin-containing regimen (conjugated equine estrogens and medroxyprogesterone acetate or micronized progestin)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 15160443

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg (E20)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg (E10)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (L10)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 749
Study: 11407965

Group type: EXPERIMENTAL
Intervention: Guided Imagery and Music (GIM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 8
Study: 9387112

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AST-120
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 80
Study: 8186349

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg b.d.
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: famotidine 20 mg b.d.
Number of subjects: 318

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 318
Study: 3285836

Group type: EXPERIMENTAL
Intervention: Torasemide (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Furosemide (500 mg/day)
Number of subjects: 10
Study: 31945015

Group type: EXPERIMENTAL
Intervention: BPZE1
Number of subjects: 12

Group type: COMPARATOR
Intervention: aPV
Number of subjects: 12
Study: 29570005

Group type: EXPERIMENTAL
Intervention: Everyday Activity Supports You (lifestyle intervention)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 28005003

Group type: EXPERIMENTAL
Intervention: Letter sent from GP to parents/carers reminding about medication (n=70 practices)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 142
Study: 24461364

Group type: COMPARATOR
Intervention: ACT group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: TEG group
Number of subjects: 82
Study: 22858176

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2a 180 μg SC
Number of subjects: 36

Group type: COMPARATOR
Intervention: PEG‐IFN alfa‐2a 90 μg IV
Number of subjects: 36